NASDAQ:PBM • CA74449F4078
The current stock price of PBM is 2.6161 USD. In the past month the price decreased by -49.93%. In the past year, price decreased by -95.79%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.45 | 404.235B | ||
| AMGN | AMGEN INC | 16.66 | 204.477B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 189.501B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 119.327B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.84 | 83.747B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.66 | 43.95B | ||
| INSM | INSMED INC | N/A | 32.227B | ||
| NTRA | NATERA INC | N/A | 29.989B | ||
| BIIB | BIOGEN INC | 12.63 | 28.491B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.499B |
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Psyence Biomedical Ltd is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
PSYENCE BIOMEDICAL LTD
121 Richmond Street West Penthouse, Suite 1300
TORONTO ONTARIO V6E 3Z3 CA
CEO: John Plourde
Employees: 12
Phone: 17744604171
Psyence Biomedical Ltd is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
The current stock price of PBM is 2.6161 USD. The price decreased by -1.47% in the last trading session.
PBM does not pay a dividend.
PBM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
You can find the ownership structure of PSYENCE BIOMEDICAL LTD (PBM) on the Ownership tab.